EDTA Lock Solution for Central Line Infection

This trial tests a solution called Tetrasodium EDTA (Kitelock™) to keep central venous catheters clear and infection-free. Central line-associated bloodstream infections (CLABSIs) can occur when catheters become blocked, so this solution aims to prevent blockages without causing issues like catheter breakage. The trial is open to children with a central venous catheter for nutrition or hydration who have a history of catheter blockages or CLABSIs. Participants must have been stable for at least four weeks with no other serious health issues. As an unphased trial, this study provides a unique opportunity to contribute to research that could enhance catheter care for many patients.

Research has shown that the 4% tetrasodium EDTA lock solution, known as KiteLock™, is generally safe for patients. Studies have found that this solution outperforms heparin, a common treatment, in maintaining catheter function and reducing infections. One study revealed that patients using KiteLock™ experienced fewer catheter-related bloodstream infections, with some cases showing a complete reduction.

No serious medical issues arose during at least four weeks of use, indicating that the treatment remains stable and safe for regular use. The solution also helps keep the catheter open and functioning properly.

Unlike most treatments for central line infections that typically involve antibiotics, the Tetrasodium EDTA Lock Solution, known as KiteLock™ 4%, offers a novel approach. This treatment acts as a catheter lock solution, which means it's directly administered into the catheter to help prevent infections. Researchers are excited about this because it uses Tetrasodium EDTA, a compound known for its ability to chelate metals and disrupt bacterial biofilms, potentially preventing infection without contributing to antibiotic resistance. This innovative approach could lead to fewer complications and better outcomes for patients with central lines.

Research has shown that a 4% solution of tetrasodium EDTA, known as KiteLock, can help keep central venous catheters clear and reduce infection risk. Studies have found it more effective than heparin in preventing blockages in children's catheters. This solution also combats biofilms, which are clusters of bacteria that adhere together and cause infections. It has proven effective against various bacteria and fungi, common culprits of infections. Overall, tetrasodium EDTA appears promising for reducing both blockages and infections in catheters. All participants in this trial will receive the Tetrasodium EDTA Catheter Lock Solution.¹⁵⁶⁷⁸